November 1, 2020 – Taiho Oncology Joins Advocacy Organizations to Support Patients and Caregivers During Gastric Cancer Awareness Month

Taiho Oncology, Inc., today announced partnerships with advocacy organizations on education programs and resources to support patients living with gastric (stomach) cancer and their caregivers as part of Gastric Cancer Awareness Month (GCAM). Patients with stomach cancer require nutritious foods in order to help them recover from treatment and maintain strength; the pandemic has had…

Read More

March 20, 2020 – Care of Individuals with Cancer During COVID-19

ASCO invited its members to submit questions about issues and challenges they see emerging while caring for individuals with cancer in the context of the coronavirus pandemic. Currently, limited clinical cancer-specific data are available and information is evolving. The following information is based on evidence gathered through a PubMed searches of the medical literature, a…

Read More

January 15, 2020 – Early-Onset Gastric Cancer, Distinct From Traditional Disease, On The Rise In US

Incidence of early-onset gastric cancer that is clinically and genetically distinct from late-onset disease has increased steadily in the United States, an “alarming phenomenon” that warrants further research, according to a study published in Surgery. “There is an increasing trend of young patients diagnosed with gastric cancer, but without any of the traditional risk factors…

Read More

January 6, 2020 – Leap, BeiGene to Develop Immunotherapy for Gastric Cancer

US based Leap Therapeutics, Inc. a biotechnology company developing targeted immuno-oncology therapeutics, and China headquartered BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, on 3 Jan 2020 announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01,…

Read More

November 12, 2019 – FDA Grants Breakthrough Status to AI-Based Gastric Cancer Diagnostic

The FDA granted breakthrough device designation to AI Medical Service’s technology for diagnosing gastric cancer, the company said Monday. The technology uses artificial intelligence to analyze endoscopy images for signs of gastric cancer, a hard-to-diagnose disease associated with a high rate of false negatives. AI Medical Service, which raised $42.9 million last month, is working to bring…

Read More

November 1, 2019 – Taiho Oncology Joins Efforts To Improve Awareness Of Gastric Cancer With Support Of Leading Advocacy Groups

Recognizing a need for greater awareness and education around gastric cancer, Taiho Oncology, Inc., today announced its support of four leading gastric cancer advocacy organizations in observance of National Gastric Cancer Awareness Month. The company is sponsoring patient and caregiver programs, education and research throughout 2019 on behalf of Debbie’s Dream Foundation, the Gastric Cancer…

Read More

October 14, 2019 – ANALYSIS OF PATIENTS WITH PRIOR GASTRECTOMY TREATED WITH LONSURF® (TRIFLURIDINE AND TIPIRACIL) PUBLISHED IN JAMA ONCOLOGY

Taiho Oncology, Inc. announced today that detailed results from the analysis of patients with prior gastrectomy enrolled in the Phase 3 TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine and tipiracil) in adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane…

Read More

July 4, 2019 – Study Uncovers Origin of Cell Layer that Hides Stomach Cancer

A group of researchers from Hiroshima recently discovered the origin of a normal-looking stomach lining that covers sites of gastric cancer and makes it difficult to spot after the eradication of an H. pylori infection. H. pylori infection is a major cause of stomach cancer and causes inflammation by releasing substances that can destroy cells…

Read More